Product Image

No Flush Niacin (Inositol Hexanicotinate) 800 mg

Life Extension
4.7
★ ★ ★ ★ ★
(3746 ratings)
Niacin 640 mg
Product Image
Score82
A high-dose no-flush niacin complex with reasonable value but confusing overlapping label amounts. It favors tolerance, not nicotinic-acid-style lipid effects.
How scoring works
Quantity:100 Capsule(s) • (100 servings)
Goals:
Heart Health
Cardiovascular Support

Score 82

A high-dose no-flush niacin complex with reasonable value but confusing overlapping label amounts. It favors tolerance, not nicotinic-acid-style lipid effects.
How scoring works
$15.75($0.15 per serving)
Pure Formulas
$ 15.75
Vitacost
$ 15.75
iHerb
$ 15.75
Report prices

Analysis

Inositol hexanicotinate is named and is intended to release niacin with less immediate flushing. Its use is better aligned with tolerance-focused B3 support than with aggressive cardiovascular expectations.

The supplied label lists the full compound alongside its niacin and inositol portions. Those values appear to describe the same material, but the presentation can be mistaken for multiple separate doses.

The total serving is substantial and well beyond routine nutrient needs. Clearer explanation of the component breakdown would make the product easier and safer to compare.

Who is it for
  • Adults seeking a high-potency no-flush form
  • Users who understand compound-versus-component labeling
  • People prioritizing niacin tolerance
Best for
  • No-flush vitamin B3 intake
  • Inositol hexanicotinate supplementation
  • High-dose tolerance-focused routines

Pros

  • Names the no-flush compound
  • Provides niacin and inositol components
  • Lower immediate flushing potential

Cons

  • Overlapping amounts are confusing
  • High amount exceeds routine needs
  • Cardiovascular effects remain less dependable

Warnings

  • Do not add the compound, niacin, and inositol lines together as separate doses without label confirmation.
  • High-dose no-flush niacin may still cause digestive or liver-related effects during long-term use.
  • It should not replace prescribed lipid management or monitored nicotinic acid use.

Nutrient quality

85 Highest impact

Inositol hexanicotinate is a clearly named no-flush niacin derivative. The substantial amount helps address the lower direct potency of this form.

.

Ingredient transparency

80 Highest impact

All meaningful active amounts are clearly disclosed. The supplied data does not include a complete inactive ingredient list.

.

Customer satisfaction

71 High impact

The aggregate satisfaction measure is strong and supported by adequate volume. Missing feedback themes leave recurring complaints and purpose fit uncertain.

.

Value for money

91 Highest impact

The price is very well matched to the formula quality and dose. Each serving provides excellent cost efficiency.

.
Report analysis

Goals

Heart Health
Impact
High effect
C- Goal FitC+ Strength of SupportC- CoverageA+ Formula Quality

The product targets lipid management through a high nominal niacin amount. It provides 640 mg of niacin from no-flush inositol hexanicotinate for the stated purpose.

No-flush inositol hexanicotinate does not provide the same established lipid effects as therapeutic nicotinic acid. High-dose niacin-related products can affect liver enzymes and blood sugar, especially alongside lipid medicines.

Study evidence
Niacin Supportive 105 studies
Cardiovascular Support
Impact
Moderate effect
D Goal FitC+ Strength of SupportF CoverageA Formula Quality
Niacin · 640 mg

Inositol hexanicotinate is marketed for lipid support, but it does not reliably deliver the effects of immediate-release nicotinic acid. Human evidence for meaningful lipid improvement with no-flush inositol hexanicotinate is limited and inconsistent.

The dose is substantial for this form, but the uncertain release of active nicotinic acid limits expected cardiovascular effect. The inositol hexanicotinate form and its component amounts are clearly disclosed. The high-dose niacin derivative warrants caution for people with liver disease or those using other liver-stressing products.

Study evidence
Niacin Supportive 136 studies

Ingredients

IngredientAmount per serving
Niacin (Inositol Hexanicotinate)
640 mg
Inositol Hexanicotinate
800 mg
Inositol (Inositol Hexanicotinate)
160 mg
Adults 18–50
Report overview
B- Active Ingredient Quality & BioavailabilityA+ Dose, Safety & Label TransparencyA+ Value

The clearly named inositol hexanicotinate offers a no-flush approach for people who want cardiovascular support without typical nicotinic acid flushing. A substantial dose helps address the lower potency often associated with this form. Strong labeling and low serving cost make it a compelling fit for users who prioritize comfort over direct nicotinic acid.

Loading alternative details
Report alternatives

Sources

Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.

  1. Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes).
    Guyton JR; Slee AE; Anderson T; Fleg JL; Goldberg RB; Kashyap ML; Marcovina SM; Nash SD; O'Brien KD; Weintraub WS; Xu P; Zhao XQ; Boden WE · Journal of the American College of Cardiology · 2013
    Randomized trial3,414 participantsCardiovascular Support forNiacin
  2. Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis.
    D'Andrea E; Hey SP; Ramirez CL; Kesselheim AS · JAMA network open · 2020
    Meta-analysis35,760 participants17 studies pooledCardiovascular Support forNiacin
  3. Supplemental Vitamins and Minerals for Cardiovascular Disease Prevention and Treatment: JACC Focus Seminar.
    Jenkins DJA; Spence JD; Giovannucci EL; Kim YI; Josse RG; Vieth R; Sahye-Pudaruth S; Paquette M; Patel D; Blanco Mejia S; Viguiliouk E; Nishi SK; Kavanagh M; Tsirakis T; Kendall CWC; Pichika SC; Sievenpiper JL · Journal of the American College of Cardiology · 2021
    Meta-analysisCardiovascular Support forNiacin
  4. The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression.
    Lavigne PM; Karas RH · Journal of the American College of Cardiology · 2013
    Meta-analysis9,959 participants11 studies pooledCardiovascular Support forNiacin
  5. Effects of niacin on apo A1 and B levels: a systematic review and meta-analysis of randomised controlled trials.
    Saboori S; Yousefi Rad E; Tammam J; Thondre PS; Coe S · The British journal of nutrition · 2024
    Meta-analysis12 studies pooledCardiovascular Support forNiacin
  6. Effect of lipid-lowering therapies on lipoprotein(a) levels: a comprehensive meta-analysis of randomized controlled trials.
    Xie S; Galimberti F; Olmastroni E; Carugo S; Catapano AL; Casula M; META-LIPID Group · Atherosclerosis · 2025
    Meta-analysis145,314 participants147 studies pooledCardiovascular Support forNiacin
  7. Effectiveness of niacin supplementation for patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
    Xiang D; Zhang Q; Wang YT · Medicine · 2020
    Meta-analysis2,110 participants8 studies pooledCardiovascular Support forNiacin
  8. Niacin improves lipid profile but not endothelial function in patients with coronary artery disease on high dose statin therapy.
    Philpott AC; Hubacek J; Sun YC; Hillard D; Anderson TJ · Atherosclerosis · 2013
    Randomized trial66 participantsCardiovascular Support forNiacin
  9. Effects of HDL-modifiers on cardiovascular outcomes: a meta-analysis of randomized trials.
    Verdoia M; Schaffer A; Suryapranata H; De Luca G · Nutrition, metabolism, and cardiovascular diseases : NMCD · 2015
    Meta-analysis69,515 participants18 studies pooledCardiovascular Support forNiacin
  10. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial.
    Elam MB; Hunninghake DB; Davis KB; Garg R; Johnson C; Egan D; Kostis JB; Sheps DS; Brinton EA · JAMA · 2000
    Randomized trial468 participantsCardiovascular Support forNiacin
  11. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group.
    Guyton JR; Blazing MA; Hagar J; Kashyap ML; Knopp RH; McKenney JM; Nash DT; Nash SD · Archives of internal medicine · 2000
    Randomized trial173 participantsCardiovascular Support forNiacin
  12. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia.
    Knopp RH; Alagona P; Davidson M; Goldberg AC; Kafonek SD; Kashyap M; Sprecher D; Superko HR; Jenkins S; Marcovina S · Metabolism: clinical and experimental · 1998
    Randomized trial223 participantsCardiovascular Support forNiacin
  13. Differential effect of two nicotinic acid preparations on low-density lipoprotein subclass distribution in patients classified as low-density lipoprotein pattern A, B, or I.
    Superko HR; McGovern ME; Raul E; Garrett B · The American journal of cardiology · 2004
    Randomized trial180 participantsHeart Health forNiacin
  14. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration.
    Villines TC; Stanek EJ; Devine PJ; Turco M; Miller M; Weissman NJ; Griffen L; Taylor AJ · Journal of the American College of Cardiology · 2010
    Randomized trial315 participantsHeart Health forNiacin
  15. The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome.
    Thoenes M; Oguchi A; Nagamia S; Vaccari CS; Hammoud R; Umpierrez GE; Khan BV · International journal of clinical practice · 2008
    Randomized trial50 participantsHeart Health forNiacin
  16. Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease.
    Duggal JK; Singh M; Attri N; Singh PP; Ahmed N; Pahwa S; Molnar J; Singh S; Khosla S; Arora R · Journal of cardiovascular pharmacology and therapeutics · 2010
    Meta-analysis5,137 participants7 studies pooledHeart Health forNiacin
  17. Effect of niacin on endothelial function: a systematic review and meta-analysis of randomized controlled trials.
    Sahebkar A · Vascular medicine (London, England) · 2014
    Meta-analysis441 participants7 studies pooledHeart Health forNiacin